Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

ATI-2231 for the Treatment of Advanced Solid Tumors

Trial Status: withdrawn

This phase Ia trial tests the safety, side effects, and best dose of ATI-2231 in treating patients with solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). ATI-2231 works by targeting a molecule called MK2, which may play a role in inflammation and bone loss. ATI-2231 may be used to slow or stop the growth of tumor cells as well as potentially to improve symptoms in patients with advanced solid tumors.